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Hyperkalemic renal tubular acidosis: Effect of furosemide in humans
and in rats. Furosemide increases urinary acidification in control
subjects and in certain patients with normokalemic or hypokalemic
distal renal tubular acidosis (RTA). We studied the effect of furosemide
in 14 patients with hyperkalemic distal RTA. In a group of patients with
pure selective aldosterone deficiency, furosemide increased net acid
and K excretion in a fashion indistinguishable from controls. This effect
of furosemide was observed both in the presence and in the absence of
acute mineralocorticoid administration. In another group of patients
with hyperkalemic distal RTA, furosemide failed to decrease urine pH
and to increase net acid excretion despite acute mineralocorticoid
administration. Plasma aldosterone was variable in this group in that
some patients had appropriate levels of aldosterone for the degree of
hyperkalemia, whereas in the other patients the levels were low. The
failure of these patients to respond to furosemide, despite
pharmacologic doses of mineralocorticoid, suggests that these patients
had a defect in H secretion other than that attributable to aldosterone
deficiency alone. To gain insight into the mechanism whereby furose-
mide increases urinary acidification, we studied control and amiloride-
treated rats pretreated with mineralocorticoid. In response to furose-
mide, control rats had a significantly lower urine pH and higher net acid
and K excretion than that observed in amiloride-treated rats. These
data suggest that furosemide increases H and K excretion, at least in
part, by creating a favorable electric gradient for secretion of these ions
since these effects were blunted in presence of inhibition of distal Na
transport by amiloride. In contrast, in patients and in rats with selective
aldosterone deficiency, furosemide increased H and K excretion,
suggesting that aldosterone is not necessary for the furosemide to
increase excretion of these ions.
Acidose tubulaire rénale hyperkaliémique: Effet du furosémide chez
I'homme et 1' rat. Le furosémide augmente l'acidification unnaire chez
les sujets contrôles et chez certains malades atteints d'acidose tubulaire
rénale distale (RTA) normokaliémiques ou hypokaliémiques. Nous
avons étudi l'effet du furosémide chez 14 malades atteints de RTA
distale hyperkaliémique. Chez des malades atteints de deficit sélectif
pur en aldostérone, le furosémide a augmenté l'excrétion acide nette et
potassique comme chez les contrôles, effet observe en presence ou en
absence d'administration aiguë de mindralocorticoIdes. Dans un autre
groupe de RTA distale hyperkaliCmique, le furosémide n'a pas été
capable de diminuer le pH urinaire et d'augmenter l'excrétion acide
nette, malgré l'administration aigud de minéralocorticoides.
L'aldostérone plasmatique etait variable dans ce groupe, les niveaux
étant appropriés chez certains, bas chez d'autres malades. La capacité
de certains de répondre au furosémide malgré des doses
pharmacologiques de minéralocorticoIdes suggére que ces malades
avaient un défaut de sécrétion d'H, autre que celui attribuable a un
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deficit en aldostérone. Afin d'étudier comment le furosémide augmente
l'acidification urinaire, nous avons utilisé des rats contrOles et traités
par l'amiloride, prétraites avec un mindralocorticoIde. Les rats contOles
avient un pH urinaire significativement plus faible, et une excretion
d'acide nette et de K plus élevée que les rats traités par l'amiloride. Ces
données suggérent que le furosémide augmente l'excrétion d'H et de
K, au moms en partie en créant un gradient electrique favorable a Ia
sécrétion des ces ions, puisque ces effets étaient supprimés par l'inhibi-
tion du transport distal du sodium par l'amiloride. A l'opposé, chez les
malades et les rats atteints de deficit sélectif en aldostérone, le
furosémide a augmente l'excrétion d'H et de K, ce qui suggére que
l'aldostérone n'est pas nécessaire au furosémide pour augmenter
l'excrétion de ces ions.
Hyperkalemic renal tubular acidosis is now a well-recognized
type of distal acidification defect. Based on previous studies, it
has been proposed that hyperkalemic renal tubular acidosis can
arise either as the consequence of selective aldosterone defi-
ciency or as the result of a tubular defect, the so-called
"voltage-dependent defect" [1—10]. Experimental and clinical
studies have suggested that urinary acidification can be in-
creased by enhancing distal Na delivery in certain subjects with
hyperkalemic distal RTA but not in others [1, 11, 12]. It has
been postulated that increasing Na distal delivery can enhance
urinary acidification, provided the distal nephron is capable of
sodium transport and the H pump is able to respond to the
favorable electric gradient [1].
Furosemide enhances acidification in animals and in normal
subjects as well as in patients with sodium retention [13—20].
We have demonstrated recently that furosemide can increase
urinary acidification in certain patients with distal acidification
defect [211. The effect of furosemide in patients with hyperkal-
ernie distal RTA has not been studied in detail. Because patients
with hyperkalemic distal RTA frequently have renal insuffi-
ciency and heart disease, the administration of mineralocor-
ticoid is not uncommonly associated with development of
volume overload. We, therefore, sought to characterize the
effect of furosernide in patients with hyperkalemic distal RTA.
If furosemide were to increase K and H excretion in these
patients, it could be potentially useful in the treatment of this
condition, either when used alone or in combination with
mineralocorticoid. In addition, we attempted to clarify the
mechanism whereby furosemide increases urinary acidification
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Table 1. Hyperkalemic patients' baseline data
Na K Cl HCO3
Blood pH Urine pH
Serum creatinine
mg%
P aldo/PK
ng %/mEq/liter
Creatinine
clearance
mi/mm Age DiagnosisPatients mEqiliter
RJ 138 5.8 109 20 7.33 5.21 2.9 0.5 22 92 Obstructive uropathy
IJ 133 6.7 103 16 7.32 5.13 2.7 1.1 87 54 Adrenalectomy
adrenal hemorrhage
JM 132 6.4 107 18 7.35 5.74 1.0 1,1 75 55 Neurogenic bladder
NC 135 5.3 99 24 7.33 6.35 2.9 1.6 77 59 Obstructive uropathy
LL 135 5.7 111 17 7.25 4.87 2.6 1.3 40 64 Obstructive uropathy
AL 129 5.2 105 18 7.34 6.02 1.2 1.2 87 57 Diabetes mellitus
CP 138 5.1 115 11 7.32 7.16 3.4 1.2 34 82 Obstructive uropathy
WR 138 6.2 112 14 7.32 5.54 5.9 4.0 25 53 Interstitial nephritis
JJ 136 6.4 106 20 7.33 6,00 3.2 2.2 31 51 Obstructive uropathy
HW* 136 5.5 108 16 7.25 5.78 2.3 0.8 26* 38 Obstructive uropathy
AT 133 6.6 101 22 7.30 6.85 4.6 3.0 19 72 Interstitial nephritis/
obstructive uropathy
RB 138 5.0 112 18 7.16 5.69 5.1 4.2 23 67 Interstitial nephritis/
obstructive uropathy
FG 127 6.9 101 19 7.30 6.70 4.7 0.5 61 52 Diabetes mellitus
ERM 140 5.6 110 20 7.35 5.72 4.7 1.6 37 59 Obstructive uropathy
* Data for clearance study obtained from nephrostomy tube representing clearance values for only one kidney.
Abbreviation: P aldo/PK, plasma aldosterone divided by plasma K.
by studying its effects on experimental models of hyperkalemic
distal acidification defects.
Methods
Studies in humans
The patients selected for the present study had hyperkalemic
hyperchloremic metabolic acidosis. In these patients, the
hyperkalemia could not be attributed to KC1 administration, K
sparing diuretics, or acute deterioration of the renal function.
Fourteen hyperkalemic patients (13 male and one female) with
renal tubular acidosis were studied (Table 1). The age of the
patients varied from 33 to 92 yrs, with a mean age of 59.6 yrs.
Eight patients had obstructive uropathy, three had chronic
interstitial nephritis with a component of obstructive uropathy,
two had diabetes mellitus, and one had adrenal insufficiency
secondary to removal of one adrenal gland and probable hem-
orrhage of the remaining adrenal gland. The diagnosis of
adrenal insufficiency in the last patient was established by low
cortisol levels, which failed to increase with ACTH stimulation.
This patient received glucocorticoid replacement either in the
form of prednisone (5 mg/day) or dexamethasone (0.75 mg/day).
Most patients had been treated with bicarbonate or Shohl's
solution for the correction of acidosis and hyperkalemia, but
these drugs were discontinued at least 3 days prior to the day of
study. The results obtained in four patients have been reported
partially in a previous study [21].
Prior to the day of study, blood for plasma aldosterone and
potassium was obtained in the euvolemic state. In 12 studies,
fludrocortisone (Florinef®) 1 mg was given orally in the evening
before the day of study, while four studies were performed
without Florinef supplementation. Two patients (IJ, JM) were
studied twice, once with Florinef supplementation and the
second time without mineralocorticoid supplementation. Thus,
16 clearance studies were performed in 14 patients. Blood
samples were obtained through a venous heparin lock and urine
samples obtained by spontaneous voiding, except in those
patients who already had a Foley catheter. After two baseline
colections of blood and urine at 30-mm intervals were made,
furosemide 1 mg/kg body wt was given as intravenous bolus,
and further collections of blood and urine were made at 30-mm
intervals for 3 hrs. Five control subjects were also studied with
Florinef supplementation before and after furosemide adminis-
tration. The data from the control subjects have been reported
in detail previously [21]. The protocol was approved by the
Human Investigation Committee of the University of Arkansas
for Medical Sciences and Veterans Administration Medical
Center. Each patient and control subject gave an informed
consent prior to the study.
Studies in rats
Sprague Dawley rats were pretreated with deoxycorticoster-
one acetate DOCA 1.5 mg TM, the day before and the day of
study. On the day of study, the rats were anesthetized by
mactin (Promonta, Hamburg, West Germany) 10 mg/100 g body
wt by intraperitoneal injection. Tracheostomy was performed,
and jugular veins and one carotid artery were canulated for
infusion and drawing blood. The bladder was catheterized
through an abdominal incision. At the start of the experiment,
iothalamate 1125 diluted in saline (0.5k Cilml) was infused by an
infusion pump at a rate of 0.024 ml/min and continued through-
out the course of experiment for measurement of GFR. A
40-mm equilibration period was allowed before any collections
were started. Urine samples were collected under mineral oil in
pre-weighed glass vials; urine volume was determined
gravimetrically. Blood samples were collected from the carotid
artery during the middle of collection period. After a single
baseline collection of blood and urine of 1 hr duration, furose-
nude 1 mg/kg body wt was injected IV as a bolus dose, and then
it was infused at a rate of 0.3 mg/kg body wt/hr for 60 to 90 mm,
and three additional collections of blood and urine were made at
approximately 30-mm intervals. Normal saline was infused at a
rate to match urine volume.
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In rats treated with amiloride, the clearance studies were
done in an identical manner to the control rats, except that
amiloride 5 mg/kg body wt/day was injected intraperitoneally
for 3 consecutive days including the day of the study. An
additional group of rats was subjected to bilateral adrenalec-
tomy as described previously [22]. They were replaced with
glucocorticoid (dexamethasone 10 g/100 g body wt/day), were
given 0.9% NaC1 and water as the drinking solutions, and
received a normal rat chow diet. After 5 days, they were
prepared for clearance as described above. The protocol was
identical to that of control rats except for the fact DOCA was
not given.
Analytic methods
Heparinized venous blood (obtained without stasis) from
humans and arterial blood from rats and urine were analyzed for
pH and pCO2 on a gas analyzer immediately after the samples
were obtained. Serum and urine were analyzed immediately
after the samples were obtained. Serum and urine were ana-
lyzed for creatinine, Na, K, Cl, and P04. HCO3 concentration
was calculated as described previously [22]. lothalamate J12$
counts were made on blood and urine of rats. Ammonia was
measured by the Berthelot technique [23] and titratable acid
was measured as described previously [21]. In some urine
samples from rats, the titratable acid was calculated from the
concentrations of phosphate and creatinine utilizing the urine
pH and the pK for these substances. From these values,
clearance of creatinine, iothalamate clearance, plasma and
urine HCO3, fractional excretion (FE) of Na, K, and excretion
of ammonia, titratable acid, bicabonate and net acid were
calculated. Plasma aldosterone and plasma renin activity were
measured by radioimmunoassay utilizing commercial kits (Di-
agnostic Products Co., Squibb Co.).
The data were analyzed by the paired or unpaired t test
wherever appropriate. To account for the variable GFR among
the patients, the data for net acid excretion have been corrected
for GFR. The data are presented as mean SEM, and values
shown in the tables and figures correspond to the average of two
baseline collections or the period at which maximal acidification
occurred, unless otherwise specified.
Results
Baseline data of patients with hyperkalemic
hyperchloremic acidosis
Table 1 shows the plasma electrolytes, blood and urine pH,
plasma aldosterone corrected for plasma K, and creatinine
clearance in the 14 patients studied. All patients had serum K
greater than 5 mEq/liter, with a mean serum K of 5.8 0.2.
Plasma HCO3 was less 22 mEq/liter with a mean of 18.0 0.9
mEq/liter in all except one patient, and blood pH was 7.35 or
less with a mean of 7.30 0.01. It should be pointed out that
many of the patients had more severe acidosis based on the CO2
content obtained at admission, but some of these patients had
been partially treated with NaHCO3 before blood pH was
determined. Despite the presence of systemic acidosis, baseline
urine pH was above 5.5 in all except three patients (RJ, Ii, LL).
Mean plasma chloride was 108.0 mEq/liter, and it was
elevated in all patients except (NC, AT, FG). In these latter
patients, the serum chloride was slightly increased relative to
Baseline Max acid
FIg. 1. Left Urine pH before and after furosemide administration in
Group 1. Studies performed without Florinef are shown as open circles
(0) and with Fiorinef are shown as closed circles (.). Right Net acid
excretion of patients of Group 1 before and during furosemide admin-
istration. Patients without Florinef supplementation are shown as open
circles (0) and patients with Fionnef are shown as closed circles (•).
the plasma Na. Glomerular filtration rate ranged from 19 to 87
mI/mm. Patients 1 through 6 had a plasma aldosterone to plasma
K ratio less 2 with a mean of 1.1 0.2. Plasma renin activity
was low in these patients, except in the patient with adrenal
insufficiency. Patients 7 through 14 had a variable plasma
aldosterone to plasma K ratio. Three patients (WR, AT, RB)
had plasma aldosterone levels appropriate for the degree of
hyperkalemia (that is, a ratio of 3 or greater). In the remaining
patients, the plasma aldosterone to plasma K ratio was low.
Plasma renin activity was low or normal in patients 7 through
14. On the basis of the response to furosemide, the patients
could be arbitrarily divided in two groups: Group 1 (patients 1
through 6) was able to lower urine pH and to increase net acid
excretion and Group 2 (patients 7 through 14) failed to lower
urine pH and to increase net acid excretion.
Effect of furosemide on urine pH and net acid excretion in
patients with hyperkalemic distal RTA
At the time of study with furosemide, serum K had been
normalized (5.8 0.2 to 4.5 0.1 mEq/liter P < 0.001). Figure
1 (left panel) shows baseline urine pH and minimal urine pH
achieved with furosemide in Group 1. In Group 1, eight studies
were performed in six patients. Four studies were performed
with Florinef and furosemide and four studies were performed
with furosemide alone. Furosemide decreased urine pH in the
patients who had a high baseline value whereas in patients with
a low baseline urine pH, the diuretic failed to change it.
Mthough the mean urine pH of the group did not change
significantly after furosemide (5.78 0.25 vs. 5.36 0.07), the
minimum urine pH in this group was not different from that of
controls. In control subjects, furosemide decreased urine pH
from 6.19 0.13 to 5.16 0.23 P <0.001.
In normal subjects, furosemide administration increased net
acid excretion from a baseline value of 0.20 0.01 to 0.66
0.23 sEq/ml GFR P <0.05. The right panel of Figure 1 shows
that following furosemide, net acid excretion/GFR also in-
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Fig. 2. Time course of effect of furosemide on urine pH in patients of
Group 2. Symbol: • Florinef + furosemide.
creased significantly in patients of Group 1. The increase in net
acid excretion was observed in patients who did not decrease
urine pH and in patients who did not receive Florinef supple-
mentation. Net acid excretion increased from a baseline value
of 0.35 0.17 to 0.77 0.21 Eq/ml GFR P < 0.01. The
increase in net acid excretion was almost entirely due to an
increase in ammonia excretion. Thus, furosemide increased net
acid excretion both in the presence and in the absence of
mineralocorticoid replacement.
Figure 2 shows the effect of furosemide in urine pH in
patients of Group 2. In these patients, baseline urine pH was
above 5.5 and failed to decrease with furosemide (baseline urine
pH 6.23 0.20 vs. 6.19 0.16 NS). Net acid excretion was
variable during furosemide administration and while it tended to
decrease, the change did not reach statistical significarice (0.43
0.45 vs. 0.13 0.34 sEq/ml GFR).
Effect of furosemide on K excretion in patients with
hypet alemic distal RTA
Table 2 shows the effect of furosemide on urine flow, GFR,
fractional K and Na excretion. In Group 1, K excretion
achieved a maximum during the peak increase of urine flow and
of fractional sodium excretion. In the third hour, urine flow and
Na excretion decreased and there was a parallel decrease in
fractional K excretion. Glomerular filtration decreased slightly
though significantly. Serum K was unchanged (not shown).
In Group 2, baseline GFR was lower than in Group 1 and
hence fractional Na and K excretions were higher. Furosemide
elicited a comparable increase in fractional Na excretion as
Group 1, although the maximum increase in urine flow was of
lesser magnitude. Although the values of fractional K excretion
observed during furosemide administration were comparable
between the two groups, the net increase in fractional K
excretion was greater in Group 1 than in Group 2 (52.8 14.4
vs. 20.8 5.2% P < 0.05).
In control subjects, fractional K excretion increased from
Table 2. Effect of furosemide on K excretion in patients with
hyperkalemic renal tubular acidosis
Period
GFR
mi/mm
V
mi/mm
FENa
%
FEK
%
Group 1
Baseline 64.4 8.2
NS
2.3 0.7
P < 0.001
1.6 0.5
P < 0.001
22.9 4.4
P < 0.01
Period 1 67.7 8.3
P < 0.01
14.4 1.4
P < 0.0
19.0 1.8
P < 0.01
75.6 15.8
P < 0.05
Period 2 49.4 4.5 4.4 0.6
Group 2
6.7 1.5 49.0 10.1
Baseline 30.0 4.0
NS
3.0 0.9
P < 0.01
4.0 0.9
P < 0.001
55.4 10.0
P < 0.01
Period 1 31.1 2.5
P<0.0l
8.1 1.1
NS
19.4 2.1
NS
76.3 7.6
NS
Period 2 23.0 2.5 6.9 0.9 19.9 1.7 83.8 6.4
Period 1 corresponds to the peak flow observed during furosemide
administration.
Period 2 corresponds to values observed in the third hour after
furosemide administration.
14.0 2.8 to a maximum of 29.0 6.7% P < 0.025 and
fractional Na excretion from 0.5 0.1 to 2.8 1.0% P <0.01.
Effect of furosemide in control, amiloride-treated, and
adrenalectomized rats
Figure 3 shows urine pH, net acid excretion, and fractional K
excretion in control and amiloride-treated rats. Furosemide
decreased urine pH and increased net acid excretion signifi-
cantly in the control rats. Amiloride-treated rats did not develop
metabolic acidosis (blood pH 7.35 0.03), but baseline urine
pH was significantly higher than that of control rats (6.54 0.45
vs. 5.82 0.19 P <0.01). Baseline net acid excretion was lower
in the amiloride-treated rats than in controls (0.17 0.13 vs.
0.52 0.05 Eq/ml GFR P < 0.01). Although furosemide
decreased urine pH significantly in amiloride-treated rats (6.54
0.45 to 5.82 0.19 P < 0.01), the minimal urine pH achieved
in the amiloride treated rats was higher than 5.5. Indeed, the
minimal urine pH achieved in amiloride-treated rats was higher
than that observed in controls P < 0.01. Furosemide failed to
increase net acid excretion in the amiloride-treated rats.
Baseline fractional K excretion was similar in control and
amiloride-treated rats (16.2 1.3 and 16.0 6.6%), but it was
inappropriately low in the latter group considering the fact that
serum K was higher in amiloride-treated rats than in control rats
(5.0 0.23 vs. 4.2 0.2 mEq/liter P < 0.05). Furosemide
increased fractional K excretion to 62.8 6.7 and 42.0 6.0%
in control and in amioride-treated rats, respectively. GFR was
comparable between the two groups (1.97 0.40 vs. 2.22
0.39 mllmin). Following furosemide, urine flow and fractional
Na excretion increased comparably in two groups (urine flow:
control rats, 22.8 6.7 vs. 116.0 32 pjlmin P < 0.05,
amiloride rats 70.0 12.4 vs. 116 17.0 P < 0.01; fractional Na
excretion; control rats 0.6 0.3 vs. 3.8 1.2%, amiloride rats
4.2 0.9 vs. 7.8 1.0%).
Nine adrenalectomized rats replaced with glucocorticoid
were studied with furosemide. Baseline plasma electrolytes in
these animals were Na 132.0 2.0, K 5.0 0.1, Cl 108 1.5,
HCO3 20.6 0.9 mEq/liter. Blood pH was 7.32 0.01 as
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Table 3. Effect of furosemide on ADX rats
805
GFR
mi/mm
V
pi/min
FENa
%
FEK
%
Urine
pH
Net acid excretionlGFR
pEq/ml GFR
Baseline 0.92 0.10 17.0 2.7 1.5 0.2 39.7 2.1 6.02 0.07 0.41 0.13
P < 0.01 0.02 0.01 0.001 0.025
Furosemide 0.95 0.08 52.0 6.6 4.2 1.0 70.0 7.3 5.39 0.005 0.63 0.24
compared to control values of 7.36 0.02 P < 0.05. Two of the
rats failed to lower urine in response to furosemide and actually
had an increase in urine pH. Table 3 shows the data of the seven
rats that responded to furosemide. Fractional Na and K excre-
tion increased significantly and the net increase was comparable
to that of controls. Baseline fractional Na excretion was higher
in ADX than in control rats. Net acid excretion increased
significantly, although the net increase was less than that
observed in controls.
Discussion
In recent years it has been recognized that hyperkalemic
renal tubular acidosis can arise either as the consequence of
aldosterone deficiency or the result of "voltage-dependent
defect" [1—12]. Initial studies suggested that furosemide may
enhance acidification in some patients with hyperkalemic distal
RTA but not in others [21]. In the present study, we observed
that patients with pure selective aldosterone deficiency, furo-
semide enhanced urinary acidification both in the presence and
the absence of acute mineralocorticoid administration. This
enhancement of urinary acidification could not be attributed to
changes in K homeostasis because serum K had been normal-
ized at the time of the clearance study. In addition, in animals
with selective aldosterone deficiency furosemide also enhanced
urinary acidification. These observations demonstrate clearly
that mineralocorticoids are not required for furosemide to
increase W and K excretion. These findings suggest that in the
absence of volume contraction, an increase in distal delivery of
Na is capable of increasing acidification in the absence of
aldosterone. This finding is in agreement with studies in adre-
nalectomized rats, but not in the dogs, that show that NaC1
loading increases urinary acidification [22, 24]. These observa-
tions should not be interpreted as indicating that aldosterone
does not play a role in enhancement of urinary acidification by
furosemide. They simply indicate that if distal delivery of Na is
adequate, an enhancement of acidification can be observed in
the absence of aldosterone. This increase in acidification may
be subnormal, as evidenced by the fact that ADX rats had a
lower increase in acid excretion than controls in response to
furosemide.
The mechanism whereby furosemide increases acidification
has been postulated to result from an increase in distal Na
delivery and thus, enhancing the favorable electric gradient for
H secretion in the collecting duct [21, 25, 26]. Several lines of
evidence support this contention. First, the response of patients
and normal subjects to furosemide and Na2SO4 is very similar,
that is, patients who respond to furosemide also respond to
Na2SO4 infusion, while patients who failed to acidify with
furosemide also failed during Na2SO4 infusion [21, 27]. Na2SO4
infusion is thought to enhance acidification solely by creating a
favorable electric gradient [1] and thus the similarity of the
response to two agents suggests, but does not prove, that these
two agents enhance acidification by a similar mechanism.
Although this finding suggests that furosemide increases
acidification by increasing distal Na delivery, it should be
pointed out that the maximal increase in Na excretion and the
maximal enhancement acidification were not temporarily re-
lated. We have shown previously that the maximal increase in
Na excretion with furosemide ocurs in the first hour, whereas
maximal acidification is observed in the second to third follow-
ing the diuretic administration [21]. It could be argued that the
differences in response to furosemide between groups 1 and 2 in
the present study may represent possible differences in Na
excretion (because of differences in GFR) between the two
Urine p1-I NAE/GFR FEK, %
20 -
1.0
0
Baseline Max acid Baseline Max acid
Fig. 3. Effect of furosemide on urine pH, net acid
excretion, and fractional K excretion in control (0) and
amiloride-treated (•) rats.
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groups. In the baseline period, absolute Na excretions between
Group 1 and 2 were comparable (138 vs. 103 Eq/min). During
the period of maximal acidification (Period 2, Table 2), absolute
Na excretion was significantly higher in Group 2 than in Group
1(622 11 vs. 291 2 jsEq/min P < 0.001). Despite this greater
increase in Na excretion and hence greater increase in distal Na
delivery, Group 2 patients failed to enhance acidification. This
finding is in agreement with our previous study that shows a
lack of correlation between the magnitude of the increase in Na
excretion and the enhancement of H secretion [211.
To test the hypothesis that furosemide increases urinary
acidification at least in part by creating a favorable electric
gradient, we utilized amiloride, an agent that has been reported
previously by us and others to lead to a distal acidification
defect by nullifying the favorable electric gradient for H
secretion [7, 8]. In amilonde-treated animals, furosemide failed
to increase acidification normally. This finding supports the
contention that furosemide enhances acidification by augment-
ing distal Na delivery and creating a favorable electric gradient.
It should be noted, however, that although amiloride blunted
the effect of furosemide to decrease urine pH, amiloride-treated
rats did decrease urine pH significantly. It is unclear whether
this decrease in urine pH simply reflects an incomplete block-
ade of distal Na transport by amioride or is the result of an
increase in urine flow [28]. In addition, it is possible that the
decrease in urine pH reflects acidification by the medullary
collecting duct, a segment in which H4- secretion is, at least in
the rabbit, independent of Na but is influenced by aldosterone
[26]. The results of the present study do not allow distinction
among these possibilities.
It has been proposed that distal acidification defects may
arise from several different mechanisms, including aldosterone
deficiency, a secretory defect, a rate-dependent defect, a volt-
age-dependent defect, and backleak of protons. Several mech-
anisms may explain the failure of patients in Group 2 to respond
to furosemide. Some of these patients had appropriate levels of
aldosterone for the level of plasma K and thus aldosterone
deficiency cannot be implicated in the pathogenesis of the
acidification defect. Other patients in this group had low aldos-
terone levels and it could be argued that aldosterone deficiency
was the responsible factor for the acidification defect. We do
not favor this interpretation because pharmacologic doses of
mineralocorticoid failed to increase acidification in these pa-
tients. Thus, it is reasonable to postulate that these patients
have an another factor responsible for the acidification defect in
addition to aldosterone deficiency.
Two possible interpretations are available for the lack of
effect of furosemide on H secretion in patients of Group 2.
First, it has been proposed, on the basis of experimental and
clinical studies, that these patients have a defect in Na transport
in the distal nephron that cannot be corrected by
mineralocortocoid administration, the so-called "irreversible
voltage-dependent defect" [7, 10]. Furosemide would thus fail
to create a favorable electric gradient and to enhance H
secretion, It is equally possible, however, that the patients in
Group 2 had a severe derangement of the distal nehron [29],
which would render the H4- pumps ineffective (secretory de-
fect). Under these conditions, even if furosemide would create
a favorable electric gradient, the distal nephron would not
increase acidification. Obviously, it is impossible to distinguish
between these two possibilities on the basis of present clear-
ance studies. The failure of furosemide to elicit acidification in
amioride-treated rats suggests that the failure to generate an
electric gradient may impair the response to furosemide in
patients. On the other hand, the more severe impairment of
GFR in patients of Group 2 is compatible with a more severe
derangement of the distal nephron in these patients, thus
explaining their failure to respond to furosemide.
It could be argued that if K excretion failed to increase with
furosemide, this would provide evidence in support of a volt-
age-dependent defect [1, 30]. It is well-recognized, however,
that K excretion can increase simply as the result of an increase
in the tubular flow rate in the absence of distal Na transport
[31]. This concept is supported by the finding that amiloride-
treated rats increased K excretion in response to furosemide,
although in a subnormal fashion. In patients of Group 2, the net
increase in K excretion was also less than that observed in
Group 1. This could result either from a voltage-dependent
defect or from the more severe impairment of GFR.
In summary, the results of the present study demonstrate that
acute administration of furosemide increases urinary acidifica-
tion and K excretion in patients and animals with selective
aldosterone deficiency. These effects of furosemide are least in
part mediated by the increase in distal Na delivery and gener-
ation of a favorable electric gradient for the excretion of these
ions.
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